In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors

被引：0
|
作者：
Geretti, E.
Espelin, C.
Adiwijaya, B.
Coma, S.
Koncki, Z.
Sumner, P.
Dumont, N.
Garcia, G.
Bloom, T.
Janovsky, J.
Reynolds, J.
Campbell, K.
Moyo, V.
Molnar, I.
LoRusso, P.
Krop, I.
Miller, K.
Ma, C.
Munster, P.
Wickham, T.
机构：
[1] Merrimack Pharmaceut Inc, Cambridge, MA USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P4-21-40
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-21-40
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Antibody Drug Conjugate Targeted Radiosensitization of HER2 Tumors
    Advani, S. J.
    Yang, H.
    Doan, M.
    Camargo, M. F.
    Aguilera, J.
    Adams, S. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S148 - S148
  • [22] ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers
    Hamblett, Kevin J.
    Hammond, Phil W.
    Barnscher, Stuart D.
    Fung, Vincent K.
    Davies, Rupert H.
    Wickman, Grant R.
    Hernandez, Andrea
    Ding, Tong
    Galey, Adam S.
    Winters, Geoffrey C.
    Rich, Jamie R.
    Babcook, John S.
    CANCER RESEARCH, 2018, 78 (13)
  • [23] A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors
    Bergstrom, Donald A.
    Bodyak, Natalya
    Yurkovetskiy, Alex
    Park, Peter U.
    DeVit, Michael
    Yin, Mao
    Poling, Laura
    Thomas, Joshua D.
    Gumerov, Dmitry
    Xiao, Dongmei
    Ter-Ovanesyan, Elena
    Qin, LiuLiang
    Uttard, Alex
    Johnson, Alex
    Lowinger, Timothy B.
    CANCER RESEARCH, 2015, 75
  • [24] In vitro and in vivo activity of a HER2-targeted thorium-227 conjugate (HER2-TTC) in HER2 low expressing and T-DM1/trastuzumab resistant preclinical mouse models
    Karlsson, J.
    Cruciani, V.
    Grant, D.
    Ellingsen, C.
    Petros, G.
    Kristian, A.
    Hagemann, U.
    Schatz, C.
    Bjerke, R.
    Ryan, O.
    Mumberg, D.
    Cuthbertson, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E122 - E122
  • [25] Specific anti-HER2 host immunity conferred by HER2-targeted antibody drug conjugate therapy and checkpoint blockade.
    Qin, You
    Dobson, Hannah E.
    Comer, Frank I.
    Chang, Alfred E.
    Wicha, Max S.
    Li, Qiao
    CANCER RESEARCH, 2021, 81 (13)
  • [26] HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity
    Reynolds, Joseph G.
    Geretti, Elena
    Hendriks, Bart S.
    Lee, Helen
    Leonard, Shannon C.
    Klinz, Stephan G.
    Noble, Charles O.
    Luecker, Petra B.
    Zandstra, Peter W.
    Drummond, Daryl C.
    Olivier, Kenneth J., Jr.
    Nielsen, Ulrik B.
    Niyikiza, Clet
    Agresta, Samuel V.
    Wickham, Thomas J.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2012, 262 (01) : 1 - 10
  • [27] First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors
    Zhang, Jian
    Du, Yiqun
    Meng, Yanchun
    Liu, Xiaojun
    Mu, Yuxin
    Liu, Yunpeng
    Shi, Yehui
    Wang, Jufeng
    Zang, Aimin
    Gu, Shanzhi
    Liu, Tianshu
    Zhou, Huan
    Guo, Hongqian
    Xiang, Silong
    Zhang, Xialu
    Wu, Suqiong
    Qi, Huanhuan
    Li, Mengke
    Hu, Xichun
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [28] An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs
    Gandullo-Sanchez, Lucia
    Pandiella, Atanasio
    CANCER LETTERS, 2023, 554
  • [29] Surface-Available HER2 Levels Alone Are Not Indicative of Cell Response to HER2-Targeted Antibody-Drug Conjugate Therapies
    Major, Molly
    Nervig, Christine S.
    Gerland, Annette
    Owen, Shawn C.
    PHARMACEUTICS, 2024, 16 (06)
  • [30] A biparatopic HER2-targeting antibody-drug conjugate demonstrates potent antitumor activity in primary tumor models that are refractory to or ineligible for HER2-targeted therapies
    Li, J. Y.
    Perry, S. R.
    Muniz-Medina, V.
    Wetzel, L. K.
    Rebelatto, M. C.
    Bezabeh, B. Z.
    Fleming, R. L.
    Dimasi, N.
    Gao, C.
    Wu, H.
    Jenkins, D. W.
    Osbourn, J. K.
    Coats, S. R.
    CANCER RESEARCH, 2016, 76
12345